HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

LY3076226

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Bell-McGuinn, Katherine M: 1 article (12/2021)
2.	Britten, Carolyn D: 1 article (12/2021)
3.	Farrington, Daphne L: 1 article (12/2021)
4.	Kollmannsberger, Christian: 1 article (12/2021)
5.	Olszanski, Anthony J: 1 article (12/2021)
6.	Patnaik, Amita: 1 article (12/2021)
7.	Radtke, David B: 1 article (12/2021)
8.	Walker, Joan Andrews: 1 article (12/2021)
9.	Willard, Melinda D: 1 article (12/2021)
10.	Zang, Wei: 1 article (12/2021)

Related Diseases

1.	Neoplasms (Cancer) 12/01/2021 - "Dose escalation of LY3076226 beyond 5.0 mg/kg in patients with advanced tumors may be possible. " 12/01/2021 - "A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancer." 12/01/2021 - "Background We report a Phase 1 study of LY3076226, an antibody-drug conjugate composed of human IgG1 monoclonal antibody against the human FGFR3 attached with a cleavable linker to the maytansine derivative DM4 in patients with advanced or metastatic cancer. Methods This study was comprised of two parts: (A) dose escalation in patients with advanced or metastatic cancer and (B) dose expansion in patients with urothelial carcinoma with locally determined FGFR3 alterations. "
2.	Carcinoma (Carcinomatosis) 12/01/2021 - "Background We report a Phase 1 study of LY3076226, an antibody-drug conjugate composed of human IgG1 monoclonal antibody against the human FGFR3 attached with a cleavable linker to the maytansine derivative DM4 in patients with advanced or metastatic cancer. Methods This study was comprised of two parts: (A) dose escalation in patients with advanced or metastatic cancer and (B) dose expansion in patients with urothelial carcinoma with locally determined FGFR3 alterations. "
3.	Embolism (Embolus) 12/01/2021 - "LY3076226 was generally well tolerated; most of the toxicities were Grade 1 or 2. Two patients experienced treatment-related Grade 3 toxicity (embolism and decreased platelet count). "

Related Drugs and Biologics

1.	Type 3 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 3)
2.	Immunoconjugates (Immunoconjugate)
3.	Maytansine (Maitansine)
4.	Immunoglobulin G (IgG)
5.	Monoclonal Antibodies